Drug & intervention

liraglutide Pen Injector [Saxenda]

RxCUI 1653600

Clinical trials4

Recruiting0

Related conditions11

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

4 shown

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesNCT06171152 · 2024-01-26

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.NCT05285397 · 2022-03-10

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOSNCT03480022 · 2018-09-26

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 ResponseNCT03341429 · 2018-08-22

Conditions being studied

Obesity2 Acute Leukemia in Remission1 Long COVID1 Long Covid191 Morbid Obesity1 Multiple Sclerosis1 Obese1 Obesity Android1 Obesity, Morbid1 Polycystic Ovary Syndrome1 Pre Diabetes1

Research locations

Baton RougeLouisiana, United States1 ChicagoIllinois, United States1 LondonUnited Kingdom1

Leading sponsors

General Committee of Teaching Hospitals and Institutes, Egypt1 University College, London1 University of Chicago1 Woman's1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.